Liu Xingchi, Xu Shiguang, Liu Bo, Xu Wei, Ding Renquan, Wang Tong, Li Bo, Wang Xilong, Wu Qiong, Teng Hong, Wang Shumin
Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China.
Zhongguo Fei Ai Za Zhi. 2018 Nov 20;21(11):849-856. doi: 10.3779/j.issn.1009-3419.2018.11.07.
Da Vinci robotic surgery system is widely used in department of thoracic surgery. The aim of this study is to investigate the treatment outcome of stage I non-small cell lung cancer (NSCLC) via da Vinci Surgical System.
Clinical date of 347 stage I NSCLC patients, who underwent lobectomy and systematic node dissection from Jan. 2012 to Dec. 2017, were reviewed. 134 patients underwent robot-assisted thoracic surgery (RATS) and 213 patients underwent video-assisted thoracic surgery (VATS). To compare perioperative outcome (blood lose, postoperative drainage, drainage time, postoperative hospital stay, number of the LN dissection) and analyze overall survival (OS), disease free survival (DFS) of the two groups and prognostic factors.
The RATS group got less blood lose [(49±39 mL for RATS vs (202±239) mL for VATS, P<0.05] and postoperative drainage [Day 1: (248±123) mL for RATS vs (350±213) mL for VATS; Day 2: (288±189) mL for RATS vs (338±189) mL for VATS, P<0.05]. There were no significant difference for drainage time (10±5 for RATS vs 11±8 for VATS, P<0.05) and postoperative hospital stay (13±6 for RATS vs 14±9 for VATS, P<0.05) between the two groups. The RATS group harvested a more number of mean stations (5±2 for RATS vs 4±2 for VATS) and amounts (18±9 for RATS vs 11±8 for VATS) of the lymph nodes, P<0.05. There was no statistically significant difference of OS between RATS and VATS group [1-year OS: 97.3% vs 96%; 3-year OS: 89.8% vs 83.1%; 5-year OS: 87.5 % vs 70.3%; overall survival time (mean): 61 months vs 59 months, P>0.05]; corresponding there had a statistically significant difference of DFS between the two groups [1-year DFS: 93.7% vs 91.3%; 3-year DFS: 87.7% vs 68.4%; 5-year DFS: 87.7% vs 52.5%; disease free survival time (mean): 61 months vs 50 months, P<0.05]. The univariate analysis found that the amounts of the lymph nodes dissection was the prognostic factor for OS and tumor diameter, surgical approach, stations and amounts of the lymph nodes dissection were respectively the prognostic factors for DFS. However, multivariate analysis found that there was not independently factors for OS, but the tumor diameter and surgical approach were independently associated with DFS.
There was no significant difference about OS between the two groups, but the RATS got better DFS. RATS got more number of the LN dissection and less blood lose.
达芬奇机器人手术系统在胸外科广泛应用。本研究旨在探讨通过达芬奇手术系统治疗Ⅰ期非小细胞肺癌(NSCLC)的治疗效果。
回顾性分析2012年1月至2017年12月期间接受肺叶切除术和系统性淋巴结清扫术的347例Ⅰ期NSCLC患者的临床资料。134例患者接受机器人辅助胸腔镜手术(RATS),213例患者接受电视辅助胸腔镜手术(VATS)。比较两组围手术期结果(失血量、术后引流量、引流时间、术后住院时间、淋巴结清扫数量),并分析两组的总生存期(OS)、无病生存期(DFS)及预后因素。
RATS组失血量较少[RATS组为(49±39)ml,VATS组为(202±239)ml,P<0.05],术后引流量也较少[第1天:RATS组为(248±123)ml,VATS组为(350±213)ml;第2天:RATS组为(288±189)ml,VATS组为(338±189)ml,P<0.05]。两组引流时间(RATS组为10±5天,VATS组为11±8天,P<0.05)和术后住院时间(RATS组为13±6天,VATS组为14±9天,P<0.05)差异无统计学意义。RATS组平均清扫的站数(RATS组为5±2个,VATS组为4±2个)和淋巴结数量(RATS组为18±9个,VATS组为11±8个)更多,P<0.05。RATS组和VATS组的OS无统计学差异[1年OS:97.3%对96%;3年OS:89.8%对83.1%;5年OS:87.5%对70.3%;总生存时间(均值):61个月对59个月,P>0.05];相应地,两组DFS有统计学差异[1年DFS:93.7%对91.3%;3年DFS:87.7%对68.4%;5年DFS:87.7%对52.5%;无病生存时间(均值):61个月对50个月,P<0.05]。单因素分析发现淋巴结清扫数量是OS的预后因素,肿瘤直径、手术方式、清扫的站数和淋巴结数量分别是DFS的预后因素。然而,多因素分析发现OS无独立相关因素,但肿瘤直径和手术方式与DFS独立相关。
两组OS无显著差异,但RATS组DFS更好。RATS组淋巴结清扫数量更多,失血量更少。